What this pathway means
Lung-progenitor-cell approaches are a subject of clinical development. A credible proposal must identify the exact product, delivery procedure, diagnosis and study or clinical authorisation. RMC has not verified a current authorisation for the clinical use described here.
A diagnosis such as COPD, interstitial lung disease, idiopathic pulmonary fibrosis or bronchiectasis is not itself evidence of eligibility. Ask the institution for the applicable protocol or authorisation and the evidence for that exact diagnosis.
Who may be appropriate for review
Initial review is not the same as eligibility. The treating institution may consider the following factors together:
- A confirmed respiratory diagnosis from a pulmonologist
- Recent high-resolution chest CT or equivalent imaging
- Pulmonary-function testing that documents impairment
- Symptoms or progression despite appropriate standard management
- A patient medically fit enough for sampling, procedures and follow-up
- A realistic understanding that improvement is not guaranteed
Disease severity, comorbidities, prior treatment, realistic goals and ability to complete follow-up can all affect the decision.
Who may not be eligible
Common reasons a pathway may be unsuitable or require further specialist assessment include:
- Active or uncontrolled respiratory infection
- Suspected or active malignancy without specialist clearance
- Unstable heart, kidney or other major organ disease
- Inability to complete required testing or follow-up
- A diagnosis outside the programme’s intended indication
- Expectations of a guaranteed cure or immediate lung replacement
These are general screening considerations, not a definitive exclusion list. The treating institution makes the final decision.
Medical records needed
A useful review requires more than a diagnosis name. Please prepare the most recent and clinically relevant records:
- Pulmonology diagnosis and clinic notes
- High-resolution chest CT report and, when requested, image files
- Pulmonary-function tests: FEV1, FVC, FEV1/FVC and DLCO where available
- Oxygen use, six-minute walk test and exercise tolerance
- Smoking history and occupational/environmental exposure history
- Respiratory infections, sputum cultures and hospital admissions
- Current inhalers, antifibrotic drugs, oxygen and pulmonary rehabilitation history
- Cancer history, cardiovascular history and recent blood tests
Do not send unnecessary sensitive documents at first contact
Begin with a case summary. Passport copies, complete imaging archives and other sensitive files should only be transmitted through an agreed secure route after preliminary screening.
Review and treatment pathway
- Submit a respiratory case summary and recent test dates
- Administrative review identifies missing CT, function or infection information
- A respiratory institution or specialist reviews the records
- Additional tests or an in-person assessment may be requested
- If accepted, the institution issues a pathway, consent information and quotation
- Travel, collection, processing, treatment and follow-up are scheduled as instructed
The sequence can change after medical review. Do not book flights or make treatment payments until the institution has issued a written plan.
Evidence, uncertainty and limitations
Company reports and early studies are leads for further review. They cannot establish routine clinical access, long-term benefit or safety for every lung-disease subtype. Request the study design, comparator, number of participants and follow-up.
Patients should ask which endpoint is relevant to their case: lung function, exercise capacity, symptoms, exacerbations, imaging or quality of life. They should also ask how long follow-up lasted and whether the results apply to people with comparable disease.
Clinical development continues
A company or hospital report is not a substitute for the actual clinical authorisation or study protocol. Research evidence, authorisation and individual eligibility must each be established.
Risks and safety questions
No cell-based or regenerative procedure is risk-free. The risk profile depends on the product, collection procedure, route of administration, patient health and follow-up.
- Risks associated with cell or tissue collection procedures
- Infection, bleeding, anaesthesia or bronchoscopy-related complications where applicable
- Infusion or administration reactions
- Disease exacerbation or need for additional respiratory care
- Uncertain durability of benefit
- Risks not yet fully defined in long-term follow-up
Patients should receive institution-specific informed-consent information before deciding.
Cost structure
No verified current treatment price is published here. Obtain an itemised quotation only after the institution confirms the legal route and assesses the case. Diagnostics, collection, hospital care, travel and coordination may be separate.
| Cost component | What to confirm |
|---|---|
| Hospital medical fee | Procedure, cell product, hospital stay and direct clinical care |
| Pre-treatment diagnostics | Tests required before eligibility or treatment |
| Specialist consultation | Remote review, MDT or in-person consultation |
| International coordination | Case preparation, scheduling, language and patient support |
| Travel and accommodation | Flights, hotels, local transport and non-medical expenses |
A formal medical quotation should follow record review. We do not present an unverified package price as a substitute for a hospital plan.
International patient timeline
A respiratory case may require several stages: records screening, image review, pulmonary-function review, specialist assessment, additional testing, collection or sampling, cell processing, administration and follow-up. The timeline cannot be reliably estimated from diagnosis alone.
Travel duration depends on the review outcome, tests, procedure schedule and follow-up requirements. Patients should keep enough flexibility for additional assessment.